Non-alcoholic steatohepatitis (NASH) is a growing health concern that affects millions of patients worldwide. It is liver cell inflammation and death associated with a buildup of fat within the liver – liver fat that is not the result of excessive alcohol intake. Liver cell injury and death are followed by fibrosis (scar tissue) development. Approximately 5 percent of the general US adult population has NASH, and it is estimated that NASH will be the primary reason for liver transplantation among men, as well as women, by the year 2020.
The staggering public health implications of this disease have fueled research and investment toward diagnostics and treatments, but many hurdles remain. In this free webinar, a panel of speakers will explore the challenges to successfully bring effective therapies to market and how we might overcome them.
Sidney Barritt IV, MD, MSCR, Associate Professor of Medicine, Division of Gastroenterology and Hepatology, UNC School of Medicine
Dr. Barritt is an associate professor in the UNC Liver Center at the University of North Carolina, where he conducts clinical outcomes research in nonalcoholic fatty liver disease (NAFLD), general hepatology and liver transplantation. Dr. Barritt leads the UNC Liver Center’s clinical trial program in NAFLD, where he is PI on multiple phase 2 and 3 industry-sponsored clinical trials. He is also a collaborator and advisor to multiple other investigators in the allied schools of health, including the Gillings School of Global Public Health, the Eshelman School of Pharmacy and the UNC School of Dentistry.Message Presenter
Dean Corn, NASH and Liver Transplant Patient
Dean, a very appreciative liver transplant recipient, started his exhausting journey through a medical maze with a routine annual physical that identified a liver anomaly. A seemingly simple examination started a long journey, which he never could have imagined, leading to such a medical experience as a major organ transplant.Message Presenter
Ivan Jarry, Co-Founder, Managing Partner, SPRIM, and Interim CEO, Fibronostics
Ivan Jarry co-founded SPRIM in 2001, a global life sciences consulting agency that works with some of the largest multi-national companies in the world. He has been instrumental in growing the company to nearly 450 employees with 17 offices around the globe. In 2017, he saw opportunity in emerging healthcare technologies and spearheaded a partnership with Tikehau Capital to create TKS1, a venture capital fund designed to offer investment to technology companies that are transforming the healthcare and life sciences industries. As part of this, SPRIM has invested in and helped create a dozen health-focused start-up companies through SPRIM Ventures, including Fibronostics, a digital diagnostics company with proprietary algorithms to help detect and monitor the progression of liver disease.Message Presenter
Rob Riccio, PhD, Vice President, Clinical Development, Hepatology and Gastroenterology (Americas), Syneos Health
Dr. Riccio leads the gastroenterology and hepatology therapeutic area for the Americas. With almost 30 years of leadership and management expertise in all phases of global pharmaceutical and medical device development, he has held various executive-level positions in pharma and global CROs. He has been instrumental in the leadership of clinical development programs resulting in the marketing approval of eight products in gastrointestinal and hepatic disease, osteoarthritis, women and men’s health, Parkinson’s disease and infectious disease, among others. He is a member of the Liver Forum and has published over 20 peer-reviewed articles and book chapters.Message Presenter
Alastair D. Smith, MB ChB, Executive Medical Director, Clinical Solutions, Syneos Health
Alastair Smith is committed to improving the outlook for patients who have incurable, progressive forms of chronic liver disease, with the goals of reducing development of end-stage liver disease and its complications, the need for liver transplantation and premature death rates in this group. Before joining Syneos Health in 2015, he was attending hepatologist at Duke University and medical director of liver transplantation there for more than eight years. Currently, Dr. Smith works in the Medical Management and Scientific Services group, striving to deliver outstanding medical monitoring services to clients and sites working in the liver disease space.Message Presenter
Who Should Attend?
This webinar will appeal to senior professionals with an interest in hepatology, such as Chief Medical Officers and Chief Scientific Officers, as well as directors and VPs of:
- Clinical Affairs
- Clinical Development
- Clinical Operations
- Clinical Studies
- Clinical Trials
- Data Analytics
What You Will Learn
Attendees will gain insights into:
- The worldwide public health burden of NASH and its complications
- Challenges of disease diagnosis and management in a significantly asymptomatic population
- The current standard of care for NASH patients and its inadequacy of addressing the disease; strategies for future treatment options, including both monotherapy and combination therapies
- The prospect for new diagnostic tools to accelerate earlier detection of NASH
- How low NASH awareness among patients and healthcare professionals impacts clinical trial enrollment
Syneos Health™ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com.